MX2020013804A - Anticuerpos anti-psma x anti-cd28 biespecíficos y usos de estos. - Google Patents
Anticuerpos anti-psma x anti-cd28 biespecíficos y usos de estos.Info
- Publication number
- MX2020013804A MX2020013804A MX2020013804A MX2020013804A MX2020013804A MX 2020013804 A MX2020013804 A MX 2020013804A MX 2020013804 A MX2020013804 A MX 2020013804A MX 2020013804 A MX2020013804 A MX 2020013804A MX 2020013804 A MX2020013804 A MX 2020013804A
- Authority
- MX
- Mexico
- Prior art keywords
- psma
- antigen
- antibodies
- binding molecules
- bispecific antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pregnancy & Childbirth (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona moléculas de unión a antígenos, biespecíficas, que comprenden un primer dominio de unión a antígeno que se une específicamente a CD28 humano, y una segunda molécula de unión a antígeno que se une específicamente a PSMA humano. En determinadas modalidades, las moléculas de unión a antígenos, biespecíficas, de la presente invención pueden inhibir el crecimiento de tumores que expresan PSMA, como los tumores de próstata. Los anticuerpos o las moléculas de unión a antígenos, biespecíficas, de la invención son útiles para el tratamiento de enfermedades y trastornos en los que una respuesta inmunitaria regulada positivamente o dirigida e inducida es conveniente y/o terapéuticamente beneficiosa.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862688227P | 2018-06-21 | 2018-06-21 | |
US201862781930P | 2018-12-19 | 2018-12-19 | |
US201862781980P | 2018-12-19 | 2018-12-19 | |
US201962815878P | 2019-03-08 | 2019-03-08 | |
PCT/US2019/038460 WO2019246514A1 (en) | 2018-06-21 | 2019-06-21 | Bispecific anti-psma x anti-cd28 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020013804A true MX2020013804A (es) | 2021-03-31 |
Family
ID=67297279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020013804A MX2020013804A (es) | 2018-06-21 | 2019-06-21 | Anticuerpos anti-psma x anti-cd28 biespecíficos y usos de estos. |
Country Status (15)
Country | Link |
---|---|
US (3) | US11548947B2 (es) |
EP (1) | EP3810282A1 (es) |
JP (1) | JP2021527431A (es) |
KR (1) | KR20210023982A (es) |
CN (1) | CN112351820A (es) |
AU (1) | AU2019290198A1 (es) |
BR (1) | BR112020025926A2 (es) |
CA (1) | CA3104098A1 (es) |
CL (1) | CL2020003285A1 (es) |
IL (1) | IL279354A (es) |
MA (1) | MA52970A (es) |
MX (1) | MX2020013804A (es) |
PH (1) | PH12020552116A1 (es) |
SG (1) | SG11202012729YA (es) |
WO (1) | WO2019246514A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
EP3456700A1 (en) | 2013-10-18 | 2019-03-20 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
JP2023514333A (ja) * | 2020-02-18 | 2023-04-05 | エンドサイト・インコーポレイテッド | Psma発現がんを処置する方法 |
KR102607909B1 (ko) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
AU2021345124A1 (en) | 2020-09-16 | 2023-03-30 | Amgen Inc. | Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer |
EP4214234A1 (en) * | 2020-09-18 | 2023-07-26 | Regeneron Pharmaceuticals, Inc. | Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof |
CN116635425A (zh) * | 2020-11-03 | 2023-08-22 | 德国癌症研究中心公共法律基金会 | 靶细胞限制性、共刺激性、双特异性二价抗cd28抗体 |
US20220241328A1 (en) | 2021-01-11 | 2022-08-04 | Sana Biotechnology, Inc. | Use of cd8-targeted viral vectors |
US20240182572A1 (en) | 2021-04-09 | 2024-06-06 | Ose Immunotherapeutics | Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains |
WO2023015217A1 (en) | 2021-08-04 | 2023-02-09 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
US20230265218A1 (en) * | 2022-02-23 | 2023-08-24 | Xencor, Inc. | Anti-cd28 x anti-psma antibodies |
AU2023232992A1 (en) | 2022-03-07 | 2024-08-15 | Novimmune Sa | Cd28 bispecific antibodies for targeted t cell activation |
AU2023236910A1 (en) | 2022-03-14 | 2024-08-01 | LamKap Bio gamma AG | Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
WO2023193239A1 (en) | 2022-04-08 | 2023-10-12 | Peter Peizhi Luo | Anti-cd28 antibodies and methods of use thereof |
WO2023198015A1 (zh) * | 2022-04-11 | 2023-10-19 | 江苏恒瑞医药股份有限公司 | 特异性结合psma和cd28的抗原结合分子及其医药用途 |
WO2024018069A1 (en) | 2022-07-22 | 2024-01-25 | Philogen S.P.A | Anti-cd28 antibodies |
WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
WO2024030453A1 (en) | 2022-08-02 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd28 antibodies in combination with anti-pd-1 antibodies |
WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
CN117844748A (zh) * | 2022-09-30 | 2024-04-09 | 北京昌平实验室 | 肿瘤抗原特异性记忆性cd8 t细胞的鉴定、体外扩增及应用方法 |
US20240254234A1 (en) | 2022-10-21 | 2024-08-01 | Novimmune Sa | PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
US7235641B2 (en) * | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー/エスGenmab A/S | Cd20に対するヒトモノクローナル抗体 |
NZ556661A (en) * | 2005-02-18 | 2010-10-29 | Medarex Inc | Human monoclonal antibodies to prostate specific membrance antigen (PSMA) |
MY159787A (en) | 2006-06-02 | 2017-01-31 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
US20090162359A1 (en) * | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
NZ719253A (en) | 2010-02-08 | 2022-08-26 | Regeneron Pharma | Common light chain mouse |
US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20160154B1 (ar) * | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
JP7023231B2 (ja) | 2015-09-23 | 2022-02-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 最適化抗cd3二重特異性抗体及びその使用 |
EP3192810A1 (en) | 2016-01-14 | 2017-07-19 | Deutsches Krebsforschungszentrum | Psma binding antibody and uses thereof |
JP2019532017A (ja) * | 2016-07-14 | 2019-11-07 | フレッド ハッチンソン キャンサー リサーチ センター | がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物 |
MX2019003325A (es) | 2016-09-23 | 2019-08-05 | Regeneron Pharma | Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos. |
RS64691B1 (sr) | 2016-09-23 | 2023-11-30 | Regeneron Pharma | Bispecifična anti-muc16-cd3 antitela i konjugati anti-muc16 sa lekom |
SG11202012342WA (en) * | 2018-06-18 | 2021-01-28 | Eureka Therapeutics Inc | Constructs targeting prostate-specific membrane antigen (psma) and uses thereof |
AU2019405736A1 (en) * | 2018-12-19 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof |
BR112021010238A2 (pt) * | 2018-12-19 | 2021-08-24 | Regeneron Pharmaceuticals, Inc. | Anticorpos anti-cd28 x anti-cd22 biespecíficos e usos dos mesmos |
MX2021011500A (es) * | 2019-03-22 | 2021-10-22 | Regeneron Pharma | Anticuerpos multiespecificos egfr x cd28. |
EP4214234A1 (en) * | 2020-09-18 | 2023-07-26 | Regeneron Pharmaceuticals, Inc. | Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof |
-
2019
- 2019-06-21 SG SG11202012729YA patent/SG11202012729YA/en unknown
- 2019-06-21 CA CA3104098A patent/CA3104098A1/en active Pending
- 2019-06-21 MX MX2020013804A patent/MX2020013804A/es unknown
- 2019-06-21 KR KR1020217000650A patent/KR20210023982A/ko unknown
- 2019-06-21 MA MA052970A patent/MA52970A/fr unknown
- 2019-06-21 WO PCT/US2019/038460 patent/WO2019246514A1/en active Application Filing
- 2019-06-21 CN CN201980041082.5A patent/CN112351820A/zh active Pending
- 2019-06-21 JP JP2020570940A patent/JP2021527431A/ja active Pending
- 2019-06-21 US US16/448,462 patent/US11548947B2/en active Active
- 2019-06-21 AU AU2019290198A patent/AU2019290198A1/en active Pending
- 2019-06-21 BR BR112020025926-8A patent/BR112020025926A2/pt unknown
- 2019-06-21 EP EP19740131.8A patent/EP3810282A1/en active Pending
-
2020
- 2020-12-10 IL IL279354A patent/IL279354A/en unknown
- 2020-12-10 PH PH12020552116A patent/PH12020552116A1/en unknown
- 2020-12-17 CL CL2020003285A patent/CL2020003285A1/es unknown
-
2022
- 2022-12-07 US US18/077,137 patent/US20230272078A1/en active Pending
- 2022-12-07 US US18/077,139 patent/US20230303696A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11548947B2 (en) | 2023-01-10 |
CL2020003285A1 (es) | 2021-05-28 |
MA52970A (fr) | 2021-04-28 |
BR112020025926A2 (pt) | 2021-03-23 |
US20230272078A1 (en) | 2023-08-31 |
KR20210023982A (ko) | 2021-03-04 |
US20190389951A1 (en) | 2019-12-26 |
CN112351820A (zh) | 2021-02-09 |
PH12020552116A1 (en) | 2021-07-19 |
SG11202012729YA (en) | 2021-01-28 |
AU2019290198A1 (en) | 2021-01-14 |
IL279354A (en) | 2021-01-31 |
JP2021527431A (ja) | 2021-10-14 |
CA3104098A1 (en) | 2019-12-26 |
WO2019246514A1 (en) | 2019-12-26 |
US20230303696A1 (en) | 2023-09-28 |
EP3810282A1 (en) | 2021-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020552116A1 (en) | Bispecific anti-psma x anti-cd28 antibodies and uses thereof | |
PH12021551238A1 (en) | Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses Thereof | |
MX2021007497A (es) | Anticuerpos biespecificos anti-cd28 x anti-cd22 y usos de estos. | |
MY195059A (en) | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof | |
JOP20200237A1 (ar) | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها | |
JOP20160154B1 (ar) | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها | |
PH12021550031A1 (en) | BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF | |
ZA201901591B (en) | Anti¿muc16 (mucin 16) antibodies | |
EA202190315A1 (ru) | Химерные антигенные рецепторы со специфичностью к bcma и их применение | |
MX2020004410A (es) | Anticuerpos biespecificos con funciones efectoras reducidas. | |
MX2018012757A (es) | Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos. | |
MX2016011414A (es) | Anticuerpos de proteina accesoria del receptor de interleucina-1 antihumana (il1 rap) y usos de los mismos. | |
MX2017001599A (es) | Anticuerpos novedosos y sus usos. | |
PH12018501525A1 (en) | Tgfbeta 2 antibodies | |
MX2021015271A (es) | Uso de moleculas biespecificas de union a antigeno que se unen a psma y cd3 en combinacion con la estimulacion conjunta de 4-1bb. | |
MX2021015270A (es) | Uso de moleculas biespecificas de union a antigeno que se unen a muc16 y cd3 en combinacion con la estimulacion conjunta de 4-1bb. | |
EA202190089A1 (ru) | Биспецифичные антитела анти-psma x анти-cd28 и их применения | |
EA202191677A1 (ru) | Биспецифичные антитела анти-muc16 x анти-cd28 и варианты их применения | |
EA202090303A2 (ru) | Композиции антител для лечения опухолей | |
EA201991227A1 (ru) | Антитела против cd3, биспецифические антигенсвязывающие молекулы, которые связываются с cd3 и cd20, и их применения |